Overview
This document serves as an official erratum for the research article "Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence," originally published in Clinical Pharmacokinetics (DOI: 10.1007/s40262-016-0442-z). The correction addresses a recurring terminology error regarding the pharmacokinetic (PK) parameters used to evaluate the bioequivalence of topical medications.
The Role of Open Flow Microperfusion (OFM)
The original study aimed to address the challenges of proving bioequivalence for topical drugs—medications applied directly to the skin. Traditional bioequivalence studies typically rely on systemic plasma concentrations. However, for many topical treatments, drug levels in the blood are negligible and do not accurately reflect the concentration at the intended site of action within the skin.
To overcome this, the researchers utilized Open Flow Microperfusion (OFM). This technique involves the insertion of small, membrane-free probes into the dermis. A perfusate fluid is circulated through the probe, allowing for the continuous sampling of the interstitial fluid surrounding skin cells. Unlike traditional microdialysis, the membrane-free nature of OFM allows for the sampling of large or lipophilic molecules, providing a direct measurement of drug concentration within the dermal compartment.
Nature of the Correction: Dermal vs. Plasma Concentration
The erratum corrects a significant reporting error where the original text mistakenly referred to "plasma concentration" (C_max) in several key sections. In the context of dermal pharmacokinetics, this distinction is critical. The value of the OFM approach lies in its ability to measure drug levels locally in the skin, bypassing the need for systemic blood sampling.
The primary "aha moment" highlighted by this correction is the necessity of compartmental precision. Referring to a measurement as "plasma C_max" fundamentally misrepresents the biological compartment being sampled (the dermis) and creates confusion regarding the study's methodology. For regulatory bodies like the FDA, whose representatives were among the authors, precise terminology is vital for establishing new standards for topical bioequivalence.
Specific Amendments
The erratum provides specific corrections for three areas of the original publication:
- Abstract (Methods Section): The 8th sentence is corrected to change "...maximum plasma concentration" to "...maximum dermal concentration."
- Table 1 Notes: The definition of C_max is updated from "maximum plasma concentration" to "maximum dermal concentration."
- Table 2 Notes: Similarly, the definition of C_max is updated from "maximum plasma concentration" to "maximum dermal concentration."
These amendments ensure that the quantitative data presented in the original paper is correctly interpreted as representing the concentration of the drug within the skin tissue itself, rather than the systemic circulation.
Summary updated